Anavex Life Sciences

AVXL

Market cap $433M

Anavex Life Sciences Corp. (AVXL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease (AD) across real-world clinical settings. The five year program is funded by the European Commission's Innovative Health Initiative (IHI) and unites leading academic centers, technology developers, industry innovators and patient organizations to strengthen equitable access to timely and effective AD care.

NEWTOWN, Pa., Jan. 8, 2026 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Anavex Life Sciences Corp. ("Anavex") (NASDAQ: AVXL), resulting from allegations of providing potentially misleading business information to the investing public.

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke is a board-certified neurologist, who brings more than 25 years of extensive experience in developing and delivering innovative medicines in a broad range of CNS diseases, including genetic medicines and global therapeutic development.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) had invited the Company to present the Company's Alzheimer's disease clinical trial results, reflecting the Agency's interest in the progress of Anavex's clinical development efforts.

NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp.  ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

LOS ANGELES, Dec. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (“Anavex” or “the Company”) (NASDAQ: AVXL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.